AlphAIalphai — Financial news for AI agents
fool.comAUG 202 min read$ICCC

ImmuCell (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell (ICCC) reported Q2 2026 earnings with product sales of $7.2M, up 11.5% YoY, and net income per diluted share of $0.20. Gross margin decreased to 33.9% from 43.7% YoY due to manufacturing costs. The company is investing in capacity expansion and focusing on its First Defense product line, with U.S. sales growing 27.7% YoY and market share increasing to 19%. Cash and cash equivalents were $8.9M as of June 30, 2026.

Original reporting
fool.com
Published Aug 20, 2026, 11:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$ICCCNeutralMed
01

Why it matters

Earnings reveal strong sales growth but declining margins; capacity investments signal long-term expansion.

02

Market read

First earnings release for Q2 2026; provides fresh data for traders evaluating livestock biotech stocks.

03

What to watch

One-time settlement may mask underlying profitability issues.

Relevance 6/10Novelty 7/10Timing: pre-market today

Background

ImmuCell Corp provides colostrum-derived antibody products for calf health, reporting Q2 2026 results.

Company-level read

Ticker impact

$ICCCNeutralMedium confidence
Context

Q2 2026 earnings call disclosed $7.2M sales, 33.9% gross margin, and a $2M legal settlement.

Expected impact

Modest upside if market rewards top-line growth; downside risk from margin decline.

Evidence & confidence

Revenue growth offsets margin pressure; settlement provides one-time earnings lift.

Market effects

Sector

Highlights growth in animal health biotech and capacity expansion trends.

Regional

U.S. dairy sector may see increased demand for colostrum-based products.

Global

Limited to niche livestock health market.

Counterpoint

What could challenge this read

Margin compression could signal operational challenges outweigh revenue gains.

Key entities

  • Executive
    Oliver Te Boekhorst

    President and CEO, provided forward-looking statements on capacity expansion.

Read at source← All news

Related articles

AUG 14
$ICCCMed

ImmuCell Q2 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported Q2 gross margin of 33.9% of product sales, down from 43.7% a year earlier and 11.1 points below Q1 2026, citing lower output, about $150,000 in scrap, and Re-Tain cost shifts. U.S. sales rose 32.5% in H1 2026; distributor volumes grew 24% YoY. The company plans $3.5M freeze-drying and $4.5M liquids capacity expansions through 2027.

yahoo.com4 min
AUG 13
$ICCCMed

IMMUCELL CORP /DE/ (ICCC): Results of Operations and Financial Condition

IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops,

SEC EDGAR 8-K6 min
JUL 9
$ICCCMed

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.

manilatimes.net3 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min